Terms: = Breast cancer AND CARS, P49589, 833, ENSG00000110619 AND Prognosis
25 results:
1. Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.
Wang Y; Li Y; Jiang H; Zuo C; Xu W
Br J Radiol; 2024 Jan; 97(1153):237-248. PubMed ID: 38263821
[TBL] [Abstract] [Full Text] [Related]
2. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.
Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
[TBL] [Abstract] [Full Text] [Related]
3. Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy.
Franke AK; Wessolowski C; Thaden V; Müller I; Cornils K
Gene Ther; 2023 Aug; 30(7-8):603-611. PubMed ID: 36529796
[TBL] [Abstract] [Full Text] [Related]
4. The Effect of HER2 Status on Metaplastic breast cancer A Propensity Score-Matched Analysis.
Hu J; Zhang Y; Dong F; Shen J; Chen H; Li L; Huang T
Front Endocrinol (Lausanne); 2022; 13():874815. PubMed ID: 35928894
[TBL] [Abstract] [Full Text] [Related]
5. Loss of PTEN Expression, PIK3CA Mutations, and breast cancer Survival in the Nurses' Health Studies.
Wang T; Heng YJ; Baker GM; Bret-Mounet VC; Quintana LM; Frueh L; Hankinson SE; Holmes MD; Chen WY; Willett WC; Rosner B; Tamimi RM; Eliassen AH
Cancer Epidemiol Biomarkers Prev; 2022 Oct; 31(10):1926-1934. PubMed ID: 35914729
[TBL] [Abstract] [Full Text] [Related]
6. Identifying glycolysis-related LncRNAs for predicting prognosis in breast cancer patients.
Zou J; Gu Y; Zhu Q; Li X; Qin L
Cancer Biomark; 2022; 34(3):393-401. PubMed ID: 35068448
[TBL] [Abstract] [Full Text] [Related]
7. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
[TBL] [Abstract] [Full Text] [Related]
8. Increasing Mortality in Korean Patients With breast cancer: High Mortality Rate in Elderly breast cancer Population Due to Suboptimal Treatment and Other Diseases.
Choi H; Noh H; Kim KM; Cho IJ; Lim S; Han A
Cancer Control; 2021; 28():10732748211037914. PubMed ID: 34406898
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events.
Zeng KL; Sahgal A; Tseng CL; Myrehaug S; Soliman H; Detsky J; Atenafu EG; Lee Y; Campbell M; Maralani P; Husain ZA
Neurosurgery; 2021 Apr; 88(5):971-979. PubMed ID: 33475723
[TBL] [Abstract] [Full Text] [Related]
10. CAR T-cell therapy for triple-negative breast cancer: Where we are.
Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
[TBL] [Abstract] [Full Text] [Related]
11. HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
Bhattacharjee A; Rajendra J; Dikshit R; Dutt S
Breast Cancer Res Treat; 2020 May; 181(1):225-231. PubMed ID: 32236825
[TBL] [Abstract] [Full Text] [Related]
12. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract] [Full Text] [Related]
13. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies.
Yu X; Zhou S; Wang J; Zhang Q; Hou J; Zhu L; He Y; Zhao J; Zhong S
Breast Cancer; 2017 Sep; 24(5):643-657. PubMed ID: 28601917
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma.
Kwon HJ; Choi JE; Kang SH; Son Y; Bae YK
Histopathology; 2017 Jun; 70(7):1155-1165. PubMed ID: 28178752
[TBL] [Abstract] [Full Text] [Related]
15. Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of breast cancer.
Miao Y; Fan R; Chen L; Qian H
Ann Clin Lab Sci; 2016 Jul; 46(4):418-24. PubMed ID: 27466303
[TBL] [Abstract] [Full Text] [Related]
16. The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
Whilding LM; Vallath S; Maher J
Biochem Soc Trans; 2016 Apr; 44(2):349-55. PubMed ID: 27068939
[TBL] [Abstract] [Full Text] [Related]
17. Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype.
He W; Tong Y; Wang Y; Liu J; Luo G; Wu J; Zhang J
PLoS One; 2013; 8(9):e75366. PubMed ID: 24086515
[TBL] [Abstract] [Full Text] [Related]
18. [Survival after breast cancer--differences between Norwegian counties].
Kalager M; Kåresen R; Wist E
Tidsskr Nor Laegeforen; 2009 Dec; 129(24):2595-600. PubMed ID: 20029554
[TBL] [Abstract] [Full Text] [Related]
19. RACK1: A superior independent predictor for poor clinical outcome in breast cancer.
Cao XX; Xu JD; Liu XL; Xu JW; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Int J Cancer; 2010 Sep; 127(5):1172-9. PubMed ID: 20020495
[TBL] [Abstract] [Full Text] [Related]
20. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
[TBL] [Abstract] [Full Text] [Related]
[Next]
